title: Influence of celiac axis lymph nodes in the definitive treatment of esophageal cancer.
abstract: The management of patients with cancer of the distal thoracic esophagus is often made difficult by the presence of disease in the celiac axis lymph nodes. We investigated the outcome of such patients treated for cure in an attempt to better define the best treatment. The charts of all patients with esophageal cancer treated at the Department of Radiation Oncology at the Medical University of South Carolina between 1990 and 1998 were reviewed. Three groups of patients were analyzed: NoMo, N1Mo, and patients with positive celiac axis lymph nodes (M1a). Among 217 patients, 56 patients received radiotherapy with intent to cure, along with surgery, chemotherapy, or some combination of these modalities. Of these, 14 had disease of the distal esophagus with the celiac axis as their only site of distant disease. Comparison of survival curves in the three analyzed groups revealed no statistically significant differences in terms of overall survival (p = 0.3458 by the log-rank test) or disease-free survival (p = 0.5509 by the log-rank test). Patients with positive celiac axis lymph nodes as their only site of "M1" disease experienced a 2-year survival rate similar to "Mo" patients when treated with curative intent.
authors.affiliation: Department of Radiation Oncology, Wake Forest University, Winston-Salem, North Carolina, USA.
authors.forename: Bart
authors.initials: B
authors.lastname: Frizzell
authors.forename: Debajyoti
authors.initials: D
authors.lastname: Sinha
authors.forename: Todd
authors.initials: T
authors.lastname: Williams
authors.forename: Carolyn E
authors.initials: CE
authors.lastname: Reed
authors.forename: Carol A
authors.initials: CA
authors.lastname: Sherman
authors.forename: Andrew
authors.initials: A
authors.lastname: Turrisi
mesh_terms: D003131:Combined Modality Therapy; D004938:Esophageal Neoplasms / Q000401:mortality* / Q000473:pathology* / Q000628:therapy; D006801:Humans; D008207:Lymphatic Metastasis; D009367:Neoplasm Staging; D011379:Prognosis; D016019:Survival Analysis